Imatinib

Specifications

152459-95-5CAS Number

604-855-6EC Number

4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamideIUPAC Name

C29H31N7OChemical Formula

493.6 g/molMolecular Weight

Imatinib; 152459-95-5; N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Glamox; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; BKJ8M8G5HI; NSC-743414; NSC-759854; N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; DTXSID3037125; CHEBI:45783; Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-; alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide; Imatinibum; 4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide; RefChem:76; DTXCID1017125; L01XE01; Imatinib (STI571); Imatinib free base; C29H31N7O; MFCD05662257; Imatinib (INN); Imatinib Methansulfonate; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; CGP 57148B; CHEMBL941; imatinib-CD3; NSC743414; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; IMATINIB [INN]; Imatinib [INN:BAN]; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; STI; benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; Glamox (TN); CCRIS 9076; SR-01000763561; NCGC00159456-02; UNII-BKJ8M8G5HI; 152459-95-5 (free base); Imatinib base; 1iep; 1xbb; CGP057148B; Gleevec(TM); 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide; CGP 57148; Genfatinib; Imatinib, Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-; 4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl)-benzamide; 4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; Imatinib (Gleevec); Imatinib, 21; Imatinib (Standard); Imatinib, Free base; ST1571; ST 1571; ST-1571; Kinome_3724; 112GI019; IMATINIB [MI]; IMATINIB [VANDF]; STI571,GLEEVEC; GLEEVEC,STI-571; IMATINIB [WHO-DD]; Gleevec (TN) (Novartis); cid_5291; SCHEMBL3827; IMATINIB [EMA EPAR]; STI-571; IMATINIB; BIDD:GT0047; GTPL5687; orb1300957; orb1941075; orb3141244; SCHEMBL29351601; SCHEMBL29355523; BDBM13530; BDBM86734; EX-A063; GLXC-05177; HMS2089D03; HMS3244P06; HMS3244P10; HMS3244P14; HMS3656K04; HMS3715P03; HMS5081I09; Imatinib base - Bio-X trade mark; Pharmakon1600-01502276; AC-524; EBC-06061; HY-15463R; MSK159951; NSC759854; NSC800772; STK617705; AKOS000280662; CCG-101289; CS-0964; DB00619; ES-0058; FM10813; NSC 743414; NSC 759854; NSC-800772; PA-5291; SB17306; SDCCGSBI-0634386.P009; MRF-0000449; NCGC00159456-01; NCGC00159456-03; NCGC00159456-04; NCGC00159456-05; NCGC00159456-06; NCGC00159456-07; NCGC00159456-09; NCGC00159456-16; NCGC00159456-25; NCGC00159456-26; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide; BI164570; HY-15463; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; SY028029; CAS_220127-57-1; I0906; I4800; NS00009172; S2475; SW197805-5; T6230; D08066; EN300-123057; AB00698388-07; AB00698388-10; AB00698388-11; AB00698388-12; AB00698388-13; AB00698388_15; AB00698388_16; F361979; Q177094; SR-01000763561-4; SR-01000763561-6; BRD-K92723993-001-06-7; BRD-K92723993-001-12-5; BRD-K92723993-066-02-9; BRD-K92723993-066-04-5; BRD-K92723993-066-22-7; Z1546624232; 1080014-82-9; 4-(4-Me-piperazin-1-ylmethyl)-N-[4-Me-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-n[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide; BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI); IMATINIB MESYLATEGLEEVECGLIVECIMATINIBSTI571CGP 571484-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-PHENYL]BENZAMIDE; N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamideSynonyms